VBI Vaccines to Present at Upcoming Scientific Conferences
(WorldNews Finland)

World Vaccine Congress: COVID-19 panel discussion, two oral presentations highlighting Phase 3 Sci-B-Vac® data and VBI-1901 Phase 1/2a data ID Week™: Two e-poster presentations featuring Phase 3 Sci-B-Vac® data VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced upcoming presentations highlighting data from multiple clinical programs - including Sci-B-Vac®, the company`s 3-antigen hepatitis B vaccine; VBI-2900, the company`s coronavirus vaccine program; and VBI-1901, the company`s cancer vaccine immunotherapeutic - at the World Vaccine Congress Washington 2020 and ID...